Lantern Pharma Inc.
LTRN Nasdaq
SEC CIK 1763950
Follow Lantern Pharma
Weekly email: filings, results
Net income
−$7.1M
−63.3% vs same quarter last year
EPS, diluted
−$0.57
−42.5% vs same quarter last year
Operating cash flow
−$2.9M
+25.3% vs same quarter last year
Operating income
−$3.5M
+24.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$17.1M |
| FY24 | −$20.8M |
| FY23 | −$16M |
| FY22 | −$14.3M |
| FY21 | −$12.4M |
| FY20 | −$5.9M |
| FY19 | −$2.4M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$15.7M |
| FY24 | −$17.8M |
| FY23 | −$14.4M |
| FY22 | −$12.8M |
| FY21 | −$10.6M |
| FY20 | - |
| FY19 | - |
| FY18 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | $500K |
| FY22 | $2.5M |
| FY21 | $939.7K |
| FY20 | - |
| FY19 | - |
| FY18 | - |